Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Average Recommendation of “Hold” from Analysts

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has earned an average rating of “Hold” from the fourteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $41.3333.

A number of research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Stephens lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Truist Financial cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price objective for the company. in a research report on Monday, April 13th. B. Riley Financial cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Lifesci Capital cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, insider Karen M. Anderson sold 64,768 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $28.21, for a total transaction of $1,827,105.28. Following the completion of the transaction, the insider owned 62,085 shares of the company’s stock, valued at approximately $1,751,417.85. The trade was a 51.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders sold 115,887 shares of company stock worth $3,346,523. 4.09% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several large investors have recently made changes to their positions in CNTA. Millennium Management LLC lifted its position in shares of Centessa Pharmaceuticals by 52.9% during the 1st quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock worth $8,760,000 after purchasing an additional 210,737 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth about $2,176,000. Geode Capital Management LLC increased its stake in Centessa Pharmaceuticals by 44.7% during the second quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock valued at $1,149,000 after acquiring an additional 26,994 shares during the period. JPMorgan Chase & Co. increased its stake in Centessa Pharmaceuticals by 155.4% during the second quarter. JPMorgan Chase & Co. now owns 428,434 shares of the company’s stock valued at $5,630,000 after acquiring an additional 260,702 shares during the period. Finally, Legal & General Group Plc increased its stake in Centessa Pharmaceuticals by 29.2% during the second quarter. Legal & General Group Plc now owns 98,256 shares of the company’s stock valued at $1,291,000 after acquiring an additional 22,205 shares during the period. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $39.72 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53. The stock has a market capitalization of $5.93 billion, a P/E ratio of -22.19 and a beta of 1.11. The business has a 50-day moving average of $39.64 and a two-hundred day moving average of $30.87. Centessa Pharmaceuticals has a fifty-two week low of $11.77 and a fifty-two week high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, equities research analysts predict that Centessa Pharmaceuticals will post -1.65 EPS for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.